HER2+ Breast Cancer Pilot Study

Blood was drawn from 16 breast cancer patients and enriched for Circulating Tumor Cells (CTCs) using LiquidScan. Isolated cells were analyzed for HER2 positivity using FISH. Of 11 patients that tested HER2- after needle biopsy, LiquidScan revealed 2 of these to be HER2+. Except for these two patients that needle biopsy missed, LiquidScan mirrored exactly...

BioFluidica turns to blood for accurate, inexpensive cancer tests

San Diego Union Tribune | By Bradley J. Fikes, August 31, 2018 Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up chemicals, cell fragments and whole cells. But signs of disease may be exceedingly rare, and reliably picking them out has spawned an industry devoted to the task....

Scroll to top